2020

Masayuki Nishide, Takeshi Tsuda, Hidenori Inohara, Atsushi Kumanogoh ≪Respiratory Medicine and Clinical Immunology, Otorhinolaryngology-Head and Neck Surgery≫ A new approach to calm that angry nose

2020-02-06
Journal:  The Journal of Allergy and Clinical Immunology 

Osaka University-led study shows that semaphorin protein induces allergic reactions and causes formation of nasal polyps in eosinophilic chronic rhinosinusitis

Fig. Serum soluble SEMA4D levels were elevated in patients with ECRS and positively correlated with disease severity. Cell surface expression of SEMA4D on eosinophils from ECRS patients was reduced, which was due to MMP-9-mediated cleavage of membrane SEMA4D. Soluble SEMA4D induced eosinophil transendothelial migration. Treatment with anti-SEMA4D antibody ameliorated eosinophilic infiltration in sinus tissues.

Click to enlarge

Osaka, Japan – Eosinophilic chronic rhinosinusitis (ECRS) is a type of airway disease involving nasal inflammation. Many studies have attempted to understand the molecular-based pathogenesis of recurrent ECRS; none have provided a clear explanation, until now.

 

In a new study published in The Journal of Allergy and Clinical Immunology, a team led by researchers from Osaka University investigated the activity of semaphorin protein, a cell-surface molecule that participates in nervous system signaling and immune responses. They found that semaphorin protein contributes to allergic reactions and development of nasal polyps in patients with ECRS.

In ECRS, inflammation leads to development of nasal polyps containing eosinophils (a subset of white blood cells). Treatment options include sinus surgery and systemic glucocorticoids. However, the effectiveness of these treatments can be insufficient and multiple side effects can occur. Thus, targeted molecular therapies may provide novel treatment options for patients with ECRS without these drawbacks. Because semaphorin has been identified in inflamed airway tissues, it is an attractive candidate for use in such therapies.

“In this study, we found that serum levels of semaphorin proteins were elevated in patients with ECRS, and that these levels were positively associated with multiple measures of disease severity,” says Masayuki Nishide, corresponding author on the study. “We suspected that semaphorin protein played an important role in the pathogenesis of ECRS.”

The Osaka University team found that activated eosinophils expressed high levels of semaphorin protein on the cell surface, which could be released into the surrounding environment through an enzymatic reaction. This soluble form of semaphorin protein could enable eosinophils to pass through endothelial cell lining, resulting in the onset of inflammation and formation of nasal polyps.

“Our analyses revealed that, in a mouse model of ECRS, mice without semaphorin protein had less nasal inflammation than normal mice, so we tested whether blocking semaphorin with an antibody could affect inflammation in normal mice with ECRS,” says Takeshi Tsuda, lead author on the study. “As expected, we found that treatment with an anti-semaphorin antibody substantially reduced nasal inflammation in mice with ECRS.”

Based on the results in the mouse model, the Osaka team concluded that anti-semaphorin antibody could provide a new treatment option for patients with ECRS. Additionally, the increased levels of semaphorin protein in patients with ECRS suggest that semaphorin protein can be used as a biomarker for ECRS in patients with nasal inflammation.

 

The article, “Pathological and therapeutic implications of eosinophil-derived Semaphorin 4D in eosinophilic chronic rhinosinusitis,” was published in The Journal of Allergy and Clinical Immunology at DOI: 10.1016/j.jaci.2019.12.893

Summary: Eosinophilic chronic rhinosinusitis (ECRS) is a type of airway disease that involves nasal inflammation. Here, semaphorin protein was found to contribute to allergic reactions and development of nasal polyps in patients with ECRS. An Osaka University-led research team found that an anti-semaphorin antibody could reduce nasal inflammation in a mouse model of ECRS and that semaphorin protein could be a new biomarker for ECRS in patients with nasal inflammation.

Primary keyword: Medicine/Health

Additional keywords: Immunology/Allergies/Asthma, Pulmonary/Respiratory Medicine, Cell Biology, Diagnostics

 

Title: “Pathological and therapeutic implications of eosinophil-derived Semaphorin 4D in eosinophilic chronic rhinosinusitis” 

Journal: The Journal of Allergy and Clinical Immunology 

Authors: Takeshi Tsuda, Masayuki Nishide, Yohei Maeda, Yoshitomo Hayama, Shohei Koyama, Satoshi Nojima, Hyota Takamatsu, Daisuke Okuzaki, Takayoshi Morita, Takeshi Nakatani, Yasuhiro Kato, Yoshimitsu Nakanishi, Yu Futami, Yasuhiko Suga, Yujiro Naito, Hachiro Konaka, Shingo Satoh, Maiko Naito, Mayuko Izumi, Sho Obata, Ayaka Nakatani, Takashi Shikina, Kazuya Takeda, Masaki Hayama, Hidenori Inohara, and Atsushi Kumanogoh

DOI: 10.1016/j.jaci.2019.12.893

Funded by: Japan Society for the Promotion of Science, Ministry of Education, Culture, Sports, Science and Technology, Japan Agency for Medical Research and Development